Alerta

LIVE ATTENUATED BORDETELLA VACCINES CAPABLE OF PRODUCING AND SECRETING HETEROLOGOUS ANTIGENS

Resumen de: WO2025257397A1

The inventors have investigated the use of an attenuated B. pertussis strain as a live vehicle for the expression of heterologous antigens (e. g. SARS-CoV-2 N-protein) through the auto-transporter SphB1 secretion machinery. The passenger domain of Sph1 was replaced by N- protein in an expression cassette containing the pertactin signal peptide coding region and promoter region. The chimeric protein was successfully produced and secreted to the extracellular medium. Nasal administration of the live recombinant strains triggered a specific systemic cell-mediated response against N-protein. These results support the use of live attenuated B. pertussis strains as a potential vaccine platform for heterologous antigen delivery.

ANTI-SARS-COV2 SPIKE (S) ANTIBODIES AND USES THEREOF

Resumen de: US2025382353A1

The present invention includes monoclonal antibody or antigen-binding fragment thereof, methods of using, detection, recombinant vectors, host cells, kits, variants, and pharmaceutical compositions that include the antibody or antigen-binding fragment thereof that is cross-reactive and binds to different variants of a Spike protein of SARS-CoV-2 (SARS2-S).

FLAVONOID-CONTAINING COMPOSITIONS AND TREATMENT OF VIRAL DISEASES WITH SAME

Resumen de: US2025381207A1

Compositions that contain flavonoids such as hesperidin, quercetin, hesperetin, and rutin and methods of treating viral diseases such as coronavirus (e.g., SARS COV-2) infection, influenza virus infection, rhinovirus infection, and human metapneumovirus infection.

Coronavirus Spike Glycoprotein With Improved Expression and Stability

Resumen de: US2025381265A1

Provided herein are mutant coronavirus spike proteins, methods of making and using, vaccines, vectors and nucleic acids, comprising at least one of the following modifications: a short flexible peptide linker or a rigid peptide linker in place of the furin cleavage site loop to genetically link an S1 and S2 subunit; at least one additional disulfide bond; or 1, 2, 3, 4, or 5 proline mutations for greater trimeric stability, wherein the mutant coronavirus spike protein has: a higher stability or a higher level of expression when compared to a non-modified coronavirus spike protein. Coronavirus is SARS, MERS, 229E (alpha), NL63 (alpha), OC43 (beta), HKU1 (beta), SARS-CoV-2, or an emerging variant thereof. Cunent SARS-CoV-2 variants include, e.g., B.1.1.7, B.1.1.7 with E484K, B.1.135, B.1.351, P.1, B.1.427, D614G, B.1.1351, or B.1.429, Lambda (i.e., C.37), Mu (i.e., B.1.621), Omicron (B.1.1.529) or a variant (including but not limited to BA.1, BA.2, or BA.3) thereof, and others.

USE OF S PROTEIN OR P4HB PROTEIN AS TARGET IN PREPARATION OF DRUG FOR PREVENTION OR TREATMENT OF COAGULOPATHY ASSOCIATED WITH SARS-COV-2 INFECTION

Resumen de: WO2025255901A1

A use of a S protein or P4HB protein as a target in preparation of a drug for prevention or treatment of coagulopathy associated with SARS-CoV-2 infection. The S protein is the spike protein of SARS-CoV-2 virus, and the P4HB protein is human protein disulfide isomerase. By means of integrated proteomic and bioinformatic study on SARS-CoV-2 interaction networks in endothelial cells, pulmonary cells, and bronchial cells, the S protein is determined as a key contributor to the procoagulant characteristics of viruses, and the S protein plays a critical role in inducing endothelial cell dysfunction. The S protein directly interacts with P4HB by means of an RBM region thereof, and promotes the secretion of P4HB by means of a lysosomal secretion pathway, thereby promoting thrombosis both in vitro and in a mouse model. Genetic or pharmacological targeting of S-P4HB axis can alleviate coagulopathy in a mouse model. The level of P4HB and disulfide bonds of target proteins thereof are significantly altered in the plasma and leukocytes of COVID-19 patients and are closely associated with the disease severity and coagulation correlation of these patients.

COVID-19 Mucosal Antibody Assay

Resumen de: US2025383359A1

Methods and compositions are disclosed for inducing immunity against a virus such as a coronavirus in the mucosal tissue of a patient, include administering a vaccine composition to the patient by oral administration (e.g., nasal injection, nasal inhalation, oral inhalation, and/or oral ingestion). Compositions for assaying the presence of anti-viral antibodies induced by the administered vaccine or the presence of viral proteins in a saliva sample include an assay protocol for detecting neutralizing antibodies (e.g., IgA) against the virus in the saliva sample. Compositions include a kit including a stabilizing solution for the patient sample (e.g., saliva sample) and may also include conjugated aragonite particle beads for antibody or viral protein capture.

SUPERREPELLENT DOUBLY REENTRANT TOPOLOGY (DRT) SURFACE FOR PROMOTING ANTIBIOFOULING AND PREVENTION OF VIRUS CONTAMINATION

Resumen de: US2025380705A1

Doubly reentrant topology (DRT) is a unique structure. The present invention first validated the outstanding performance of an anti-biofouling artificial surface comprising a superhydrophobic surface; thereon a plurality of microstructures and having a doubly re-entrant topology (DRT) situated atop respective base structures which demonstrates a striking anti-biofouling effect that can prevent viral contamination. Furthermore, the present invention per se features excellent anti-biofouling ability, which may shed light on the applications of pathogen elimination in alleviating the COVID-19 pandemic.

METHODS OF TREATING SARS-COV-2 INFECTIONS

Resumen de: ZA202210474B

The disclosure is directed to methods of using dantrolene or a dantrolene prodrug, or a pharmaceutically acceptable salt thereof, to treat COVID-19 and SARS-CoV-2 infections.

DIAGNOSIS OF RESPIRATORY DISEASES BY CAPTURING AEROSOLIZED BIOMATERIAL PARTICLES USING PACKED BED SYSTEMS AND METHODS

Resumen de: ZA202309169B

Methods and devices for capturing and analyzing aerosolized particles in exhaled breath characteristic of a respiratory disease to enable rapid, low-cost point of care assays for several diseases including respiratory tract diseases such as COVID-19 are disclosed. The disclosed methods and systems selectively capture aerosolized particles using a packed bed column. The captured particles are then eluted using solvents and analyzed using analytical devices including MALDI-TOFMS.

RECOMBINANT VACCINE AGAINST COVID-19 TO PRODUCE CELLULAR RESPONSE IN INDIVIDUALS WITH PRE-EXISTING IMMUNITY

Resumen de: US2025375515A1

A recombinant vaccine is described, which comprises an active Newcastle disease viral vector (NDV) having inserted an exogenous nucleotide sequence of severe acute respiratory syndrome coronavirus 2 (SARS-COV-2), without adjuvant, capable of generating a significant cellular response in T cells (CD4+ or CD8+) when stimulated with the S protein of the SARS-CoV-2 virus or proteins derived from it in individuals with previous immunity.

SARS-COV-2 MPRO INHIBITORS AND USES THEREOF

Resumen de: WO2025253129A1

This application relates to novel compounds and their use as SARS-CoV-2 Main Protease (Mpro) inhibitors. Compounds described herein may be useful in the treatment of SARS-CoV-2 and related viruses and disorders associated with SARS-CoV-2: Mpro. The application is also directed to pharmaceutical compositions comprising these compounds and the manufacture and use of these compounds and compositions in the treatment of SARS-CoV-2 and related viruses and disorders associated with SARS-CoV-2: Mpro. The compounds and compositions may be useful in preventing death or complications arising due to chronic underlying conditions or comorbidities in patients infected with SARS-CoV-2 and related viruses.

SARS-COV-2 VACCINE COMPOSITIONS

Resumen de: AU2024263334A1

Disclosed herein are coronavirus (CoV) Spike (S) polypeptides, including naturally and non-naturally occurring polypeptides, and nanoparticles and immunogenic compositions comprising the same, which are useful for stimulating immune responses against various SARS-CoV-2 strains. The nanoparticles present antigens from pathogens surrounded to and associated with a detergent core resulting in enhanced stability and good immunogenicity. Dosages, formulations, and methods for preparing the vaccines and nanoparticles are also disclosed.

SERINE PROTEASE INHIBITORY EFFECTS OF HEALTH SUPPLEMENTS IN HUMAN CANCEROUS CELL LINES

Resumen de: US2025375416A1

The present invention relates generally to a method of detecting inhibitory effects of health supplements on serine protease in cell lines derived from human carcinomas. More, particularly, the present invention relates to inhibitory analysis of health supplementary products taken from market and/or chemically purified forms, in order to determine their competitors and/or inhibitory effects on serine protease such as trypsin so that these supplements can be used for the treatment once someone develop intense inflammatory reactions either due to infections like COVID-19 and/or pathological conditions such as cancer. The present invention further provides therapeutic applications for agents and/or condition which utilize human enzymatic system and/or cellular components for the development of pathological conditions.

Compounds for treatment a coronavirus infection

Resumen de: US2025376464A1

The present invention is generally directed to inhibitors of SARS-CoV-2-related 3C-like protease (Mpro) useful in the treatment of coronavirus infection and having the Formula (A):

COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTION USING MITOCHONDRIAL MODULATION

Resumen de: WO2025255479A1

Methods and compositions for the treatment of viral infections, such as SARS-CoV-2 infection, are disclosed herein which restore mitochondrial function, thereby inhibiting viral propagation.

COMPOSITION CONTAINING HOTSPOT-DERIVED PEPTIDE-NUCLEIC ACID HYBRID MOLECULE FOR TREATING INFECTION CAUSED BY MUTATED CORONAVIRUS

Resumen de: US2025376490A1

The present disclosure relates to a composition for preventing or treating coronavirus infection, including a hotspot-derived peptide-nucleic acid hybrid molecule. It was confirmed that in vitro evolution-based hotspot-derived peptide-nucleic acid hybrid molecule prepared using the method of the present invention has high binding affinity for the RBDs of SARS-COV-2 VOCs (alpha, beta, gamma, delta, and omicron). In particular, it was found that the greatest binding tolerance was exhibited in the most highly mutated omicron. Furthermore, the hybrid molecule showed high RBD binding affinity in competition with RBD-binding nucleic acid aptamers, macrocyclic peptides, and monoclonal antibodies. The hybrid molecule also exhibited excellent nuclease resistance and serum stability, indicating potential as virus neutralizer in addition to SARS-COV-2.

IN VITRO METHOD FOR PREDICTING MORTALITY IN COVID-19 PATIENTS

Resumen de: WO2022135752A1

The present invention refers to the in vitro use of a Coronavirus antigen, measured in plasma, serum or blood samples obtained from the patient, for the prognosis and/or for predicting the mortality risk of patients suffering from Coronavirus infection, for predicting the response of patients suffering from Coronavirus infection to an antiviral therapy or for selecting patients suffering from Coronavirus infection for receiving an antiviral therapy.

SARS-CoV-2 PPC SARS-CoV-2 PEPTIDE THAT SPECIFICALLY BINDS TO PPC REGION OF SARS-COV-2 SPIKE PROTEIN AND COMPOSITION FOR PREVENTING SARS-COV-2 INFECTION USING THE SAME

Resumen de: US2025368755A1

Disclosed are a peptide specifically binding to a PPC region of a SARS-CoV-2 spike protein and a composition for preventing SARS-CoV-2 infection using the same. The peptide includes a peptide sequence of DGRARQSQDDD or GSQIALRRRDE.

Covid-19 Covid-19-Cov-2 Cov-19 PRIMER PROBE AND CONTROLS FOR DETECTION AND DISCRIMINATION OF COVID-19 AND OTHER CORONAVIRUSES DIAGNOSTIC ASSAY FOR THE HUMAN VIRUS CAUSING COVID-19-COV-2COVID-19 AND ITS VARIANTSPRIMER PROBE AND CONTROLS FOR DETECTION AND DISCRIMINATION OF COVID-19 AND OTHER CORONAVIRUSES DIAGNOSTIC ASSAY FOR THE HUMAN VIRUS CAUSING COVID-19-COV-2COVID-19 AND ITS VARIANTS

Nº publicación: KR20250170783A 08/12/2025

Solicitante:

문정주